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Summary
Background Arterial hypertension is one of the major cofounders in the development of atrial fibrillation (AF) and 
hypertension is commonly found in AF patients. The aim of the study was to establish the prevalence of arterial 
hypertension in patients undergoing ablation, who are relatively young and healthy group of AF patients. 
Material and methods 266 consecutive patients admitted for AF ablation were screened for arterial hypertension. 
All patients had their blood pressure measured on admission by, prior to the ablation procedure by a qualified physi-
cian, according to the current guidelines. Also, medical records of patients were reviewed for the previous diagnosis 
of hypertension or taking hypotensive agents.
Results The study group was predominantly male (65.0%; mean age 57.6 ±  10.1 years). Mean body mass index 
was 29.7 ±  5.0 kg/m2. Paroxysmal AF was present in 69.5% of patients. In 72.9% of patients hypertension was 
diagnosed previously. On admission, mean systolic and diastolic blood pressure values were 131.7 ±  16.7 and 80.7 
±  11.1 mm Hg. 123 (46.2%) patients had systolic and/or diastolic blood pressure values respectively >  140  and/ 
/or  >  90 mm Hg. Patients with previously diagnosed hypertension were older (58.7 ±  8.7 vs 54.6 ±  12.7 years;  
p =  0.003), had higher BMI (30.3 ±  5.0 vs 28.1 ±  4.8 kg/m2; p =  0.002), and more often history of diabetes (10.8% 
vs 1.4%; p =  0.03) compared to non-hypertensive group. There were no differences in terms of history of dyslipi-
daemia, stroke, myocardial infarction or family history of cardiovascular disease.
Conclusions In patients with AF undergoing ablation procedure, prevalence of diagnosed arterial hypertension 
is very high, much higher than in the general population. Nevertheless, majority of patients meet the criteria for 
adequate blood pressure control.
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Background
Arterial hypertension and atrial fibrillation (AF) are 
one of the most prevalent diseases of the cardio-
vascular system. The incidence of both conditions 
increases with advancing age [1]. Therefore, due to 
the prolonging life expectancy, the total number of 
patients with arterial hypertension and AF is expect-
ed to grow in the forthcoming years. Both AF and 
arterial hypertension are responsible for considerable 
morbidity and mortality. Their coexistence further 
increases the risk and affects management of patients 
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and treatment strategies. Currently, the treatment 
of arterial hypertension depends mostly on lifestyle 
modifications and pharmacotherapy, with invasive 
treatment still playing only a minor role in everyday 
practice [2]. Whereas, the treatment of AF, namely 
pursing the rhythm-control strategy, in many cases is 
achieved through catheter ablation. Current guide-
lines recommend ablation as one of the treatment 
options in patients with symptomatic AF in spite 
of an antiarrhythmic drug therapy or as first-line or 
second line therapy in selected patients, which prefer 
this kind of treatment [3, 4]. Unfortunately, effec-
tiveness of AF ablations remains limited, partially 
due to poor control of risk factors for the arrhythmia 
recurrence, which include diabetes, metabolic syn-
drome, or left atrial dimensions [5]. Arterial hyper-
tension contributes to the development of AF itself, 
as well as the established AF-recurrence predictors. 
Therefore, screening for arterial hypertension in AF 
patients and describing the profile of hypertensive 
patients, especially those undergoing ablation is of 
great importance.
Material and methods
We performed a prospective, observational, cohort 
study in order to establish the prevalence of arterial 
hypertension in consecutive Polish patients undergo-
ing catheter ablation for AF. The study was conduct-
ed with respect to the Declaration of Helsinki. The 
study protocol was approved by the Ethics Commit-
tee by the Medical University of Warsaw and a writ-
ten, informed consent was obtained from every study 
participant prior to the study enrolment.
The study cohort consisted of 266 consecutive 
patients who were hospitalized in a high-volume ter-
tiary university cardiology clinic, where they were ad-
mitted for first-ever ablation for AF. All patients were 
qualified for the ablation procedure following the 
European Society of Cardiology (ESC) guidelines for 
the management of AF from 2010 and 2012 [3, 4]. 
The study protocol was described in detail previously 
[5, 6]. Exclusion criteria were age < 18 or ≥ 75 years, 
prior ablation of AF, MI, stroke or decompensation 
of heart failure within the last six months, untreated 
overt hyper- or hypothyroidism, current treatment 
with a continuous positive airway pressure device, 
and absence of written informed consent.
AF diagnosis was made based on at least one epi-
sode of the AF recorded in a 12-lead electrocardio-
gram (ECG) or an episode of documented AF in 
a 12-lead ECG and/or 24-hour ECG Holter mon-
itoring in 6 months prior to the study enrolment. 
AF was defined as at least 30 seconds of an irregular 
heart rhythm with no distinct P waves, and irregular 
RR intervals. In all cases the diagnosis was made by 
two independent expert cardiologists. Paroxysmal 
AF was defined as a self-terminating episode, where-
as persistent AF was diagnosed when arrhythmia 
episode either lasted longer than 7 days or required 
termination by cardioversion. There were no cases of 
permanent AF in the study population because this 
diagnosis is made only if it was decided not to pursue 
rhythm control strategy.
All study participants were screened for arterial 
hypertension. Patients had their blood pressure mea-
sured on admission, prior to the ablation procedure, 
by a qualified physician Diagnosis of arterial hyper-
tension was made when office blood pressure were 
equal or exceeded the values of 140 for systolic blood 
pressure (SBP) and/or 90 for diastolic blood pressure 
(DBP). The number of required measurements, mea-
sure techniques and settings were in accordance with 
the current guidelines for arterial hypertension dia-
gnosis and management of the ESC and European 
Society of Hypertension [2]. The diagnosis was also 
made were there were eligible medical records avail-
able on previous diagnosis of arterial hypertension or 
taking prescription hypotensive agents.
All patients were also screened for other classical 
and non-classical cardiovascular risk factors includ-
ing diabetes mellitus, dyslipidaemia, or history of 
cardiovascular disease. Diagnosis of all factors was 
made based on eligible medical records, taking pre-
scription drugs applicable for the respective disease 
(i.e. hypoglycaemic agents for diabetes), or as a de 
novo diagnosis according to the current diagnostic 
criteria. 
Statistical analysis was performed using the SAS 
software version 8.02 (SAS Institute, Inc., Cary, NC, 
USA). Continuous data are presented as mean ± 
standard deviation (SD) and were compared using 
the Mann-Whitney test or Student’s t-test. Cate-
gorical variables were compared using either the c2 
or Fisher exact tests. A p value of less than 0.05 was 
considered statistically significant, whereas the con-
fidence intervals (CI) were 95%. 
Results
This prospective cohort study covered 266 patients 
undergoing first-ever ablation for AF. The mean age 
of the study population was 57.6 ± 10.1 years and 
65% of patients were male. The body mass index 
(BMI) in the study population was 29.7 ± 5.0 kg/m2 
and 69.5% of patients had paroxysmal AF, while 
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Table 1. Baseline characteristics of the study population
Parameter Value
n = 266
Age (years)  57.6 ± 10.1
BMI [kg/m2]  29.7 ± 5.0
SBP [mm Hg]  131.7 ± 16.7
DBP [mm Hg]  80.7 ± 11.0
HR (beats per minute)  75.0 ± 15.8
History of myocardial infarction 22 (8.3%)
Diabetes mellitus 17 (6.4%)
Previously diagnosed arterial hypertension 194 (72.9%)
Smoking 28 (10.5%)
History of stroke or TIA 22 (8.3%)
Dyslipidaemia 167 (62.8%)
Thyroid disease 68 (25.6%)
Family history of cardiovascular disease 104 (39.0%)
Paroxysmal AF 185 (69.5%)
Parameters are presented as mean ± standard deviation or n (%) 
BMI — body mass index, SBP — systolic blood pressure, DBP — diastolic blood pressure, HR — heart 
rate, TIA — transient ischaemic attack, AF — atrial fibrillation
the rest was diagnosed with persistent AF. Detailed 
characteristics of the study population are listed in 
the Table 1.
As for the mean SBP and DBP values they were 
131.7 ± 16.7 and 80.7 ± 11.0 mm Hg, respective-
ly (Figure 1). One hundred ninety-four patients 
(72.9%) were previously diagnosed with arterial hy-
pertension, while the values exceeding the threshold 
of ≥ 140 and/or 90 mm Hg on admission were 
found in 46.2% of patients. No data were available 
in the medical records on the degree of the previously 
diagnosed hypertension prior to the implemented 
treatment.
After dividing patients according to the presence 
of previously diagnosed arterial hypertension it was 
found that patients with the disease were older 
(58.7 ± 8.7 vs 54.6 ± 12.7 years; p = 0.003), and 
had higher BMI (30.3 ± 5 vs 28.1 ± 4.8 kg/m2; 
p = 0.002) than patients without the diagnosed arte-
rial hypertension. As for the prevalence of comorbid-
ities it was found that hypertensive patients more of-
ten had diabetes mellitus (10.8% vs 1.4%; p = 0.03) 
compared with patients without the diagnosis. SBP 
values were significantly higher in patients with 
previously diagnosed arterial hypertension (133.6 ± 
16.1 vs 126.7 ± 17.6 mm Hg; p = 0.003) than those 
without the disease. No differences between the 
groups were found in terms of DBP (81.4 ± 11.4 
vs 78.9 ± 10.1 mm Hg; p = 0.1).
No differences were seen in terms of the preva-
lence of other cardiovascular risk factors including: 
Figure 1. Mean blood pressure on admission
history of myocardial infarction or stroke, dyslipi-
daemia, smoking and family history of cardiovascular 
disease (p > 0.05). The detailed information on the 
groups characteristics are presented in Table 2.
Discussion
The present study concerned patients undergoing 
ablation for AF. This group is somehow different 
from the general population of AF patients due to 
a number of factors. While there is no strict age 
limit for the catheter ablation procedure, it is rarely 
performed in patients older than 75 years [8]. More-
over, number of contraindications for the procedure 
contributes to lower number of comorbidities in AF 
ablation recipients. Therefore, compared to the unse-
lected groups of AF patients, those undergoing ablation 
procedure tend to be in better general health and have 
lower comorbidity rate. As it was shown in the present 
study, the mean age of the participants was 57.6 years, 
whereas in the AF general population it tends to be over 
70 years [9]. Nevertheless, the prevalence of arterial 
hypertension in the present group was high (72.9%), 
almost twice as high as in the corresponding age group 
of the general population [10]. Higher prevalence of the 
disease is attributable to two factors. First of all, prior to 
the ablation all patients were screened and treated by 
specialists therefore the rate of underdiagnosed cases of 
arterial hypertension remains low in this population. 
Second of all, there is a strong relationship between 
hypertension and development of AF.
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Table 2. Patients’ characteristics according to the presence of previously diagnosed hypertension. 





Age (years)  58.7 ± 8.7  54.6 ± 12.7 0.003
BMI [kg/m2]  30.3 ± 5  28.1 ± 4.8 0.002
SBP [mm Hg]  133.6 ± 16.1  126.7 ± 17.6 0.003
DBP [mm Hg]  81.4 ± 11.4  78.9 ± 10.1 0.1
HR (beats per minute)  76.4 ± 16.5  71.1 ± 13.2 0.06
History of myocardial infarction 18 (9.3%) 4 (5.6%) 0.46
Diabetes mellitus 21 (10.8%) 1 (1.4%) 0.03
Smoking 20 (10.3%) 8 (11.1%) 0.85
History of stroke or TIA 18 (9.3%) 4 (5.6%) 0.47
Dyslipidaemia 124 (63.9%) 43 (59.7%) 0.62
Thyroid disease 52 (26.8%) 16 (22.2%) 0.45
Family history of cardiovascular disease 77 (39.7%) 27 (37.5%) 0.89
Paroxysmal AF 129 (66.5%) 56 (77.8%) 0.08
Parameters are presented as mean ± standard deviation or n (%) 
BMI — body mass index, SBP — systolic blood pressure, DBP — diastolic blood pressure, HR — heart rate, TIA — transient ischaemic attack, AF — atrial fibrillation
terial hypertension in AF patients was higher than 
50%, and it was thought to be a sole cause of the AF 
in 15% of patients [12–14]. The proposed mecha-
nism in which arterial hypertension causes the AF 
involves the structural changes in the left atrium that 
include left atrial stretch and enlargement, changes in 
left atrial mechanical function, altered left atrial elec-
trophysiology, and increased atrial ectopic activity. 
Mostly, due to haemodynamic overload [15].
Other contributors to the AF development that 
were described in the literature involve advanced 
age, obesity, smoking, diabetes mellitus, thyroid dys-
function, or history of diseases such as heart valve 
disease, heart failure, myocardial infarction [16]. In 
the present study patients with previously diagnosed 
arterial hypertension were older, had higher BMI and 
higher prevalence of diabetes mellitus. As they are all 
contributors to the development of arrhythmia itself, 
there is a possibility that in this cohort, the hyper-
tensive patients will be predisposed to higher risk of 
transition to the permanent form of the arrhythmia 
in the future or lower success rate after the ablation 
procedure.
Data on the impact of hypertension itself on the 
ablation procedure vary across the literature. Studies 
focused on establishing the parameters predictive of 
AF recurrence after the procedure do not identify 
arterial hypertension as one of the risk factors [17] or 
even list hypertension as one of the procedure success 
predictors [18]. This may be partially attributable 
to the fact that most of the AF ablation recipients 
with hypertension receive hypotensive treatment on 
Figure 2. Prevalence of previously diagnosed arterial hypertension 
versus patients with blood pressure values meeting the criteria for 
hypertension diagnosis
BP — blood pressure, HT — arterial hypertension
Arterial hypertension is a disease associated with 
haemodynamic changes in the whole cardiovascular 
system, which lead to changes and damage to the 
end-organs. Cohort epidemiological studies of hy-
pertensive patients show that those who subsequent-
ly developed AF had higher mean systolic blood 
pressure values than those who maintained the sinus 
rhythm [11]. In other studies the prevalence of ar-
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hospital discharge and the reduction of blood pressure 
values both pharmacological and invasive are associ-
ated with improvement of the success rate [19, 20]. 
Moreover, the successful procedure itself was de-
scribed to be associated with a significant decrease 
in the systolic blood pressure values [21]. As the 
treatment of hypertension may reverse the structural 
changes in the heart, the optimistic finding of the 
present study was the in spite of high arterial hyper-
tension prevalence, the mean SBP and DBP values 
were relatively low, which points to a good blood 
pressure control in this cohort.
Conclusions 
Patients with AF undergoing ablation are a relatively 
young group, with a low comorbidity rate. Neverthe-
less, in this group of patients, prevalence of diagnosed 
arterial hypertension is very high, much higher than 
in the age corresponding group from the general pop-
ulation. Patients with diagnosed hypertension tend to 
be older, have higher BMI, and more often history of 
diabetes. Nevertheless, the mean SBP and DBP values 
on admission were not significantly elevated, which 
shows that the majority of patients meet the criteria 
for adequate blood pressure control. 
References
1. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a caus-
ative agent, risk factor for complications, and potential therapeutic 
target. Am. J. Cardiol. 2003; 91: 9G–14G.
2. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines 
for the management of arterial hypertension: the Task Force for the 
Management of Arterial Hypertension of the European Society of 
Hypertension (ESH) and of the European Society of Cardiology 
(ESC). Eur. Heart J. 2013; 34: 2159–2219.
3. Camm A.J., Kirchhof P., Lip G.Y. et al. European Heart Rhythm 
Association; European Association for Cardio-Thoracic Surgery. 
Guidelines for the management of atrial fibrillation: the Task Force 
for the Management of Atrial Fibrillation of the European Society of 
Cardiology (ESC). Eur. Heart J. 2010; 31: 2369–2429.
4. Camm A.J., Lip G.Y., De Caterina R. et al. ESC Committee for Prac-
tice Guidelines (CPG). 2012 focused update of the ESC Guidelines 
for the management of atrial fibrillation: an update of the 2010 ESC 
Guidelines for the management of atrial fibrillation. Developed with 
the special contribution of the European Heart Rhythm Association. 
Eur. Heart J. 2012; 33: 2719–2147.
5. Cai L., Yin Y., Ling Z. et al. Predictors of late recurrence of atrial 
fibrillation after catheter ablation. Int. J. Cardiol. 2013; 164: 82–87.
6. Szymański F.M., Płatek A.E., Karpiński G., Koźluk E., Puchalski 
B., Filipiak K.J. Obstructive sleep apnoea in patients with atrial 
fibrillation: prevalence, determinants and clinical characteristics 
of patients in Polish population. Kardiol. Pol. 2014; 72: 716–724.
7. Szymanski F.M., Filipiak K.J., Platek A.E. et al. Presence and severity 
of obstructive sleep apnea and remote outcomes of atrial fibrillation 
ablations — a long-term prospective, cross-sectional cohort study. 
Sleep Breath. 2015 Jan 8. doi: 10.1007/s11325-014-1102-x [Epub 
ahead of print].
8. Chen J., Hocini M., Larsen T.B., Proclemer A., Sciaraffia E., Blom-
ström-Lundqvist C. Scientific Initiative Committee, European Heart 
Rhythm Association. Clinical management of arrhythmias in elderly 
patients: results of the European Heart Rhythm Association survey. 
Europace 2015; 17: 314–317.
9. Hrynkiewicz-Szymanska A., Dluzniewski M., Platek A.E. et al. 
Association of the CHADS2 and CHA2DS2-VASc scores with left 
atrial enlargement: a prospective cohort study of unselected atrial 
fibrillation patients. J. Thromb. Thrombolysis 2015; 40: 240–247. 
10. Zdrojewski T., Bandosz P., Rutkowski M. et al. Rozpowszechnienie, 
wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce 
— wyniki badania NATPOL 2011. Nadciśnienie Tętnicze 2014; 
18: 116–117.
11. Ciaroni S., Cuenoud L., Bloch A. Clinical study to investigate the 
predictive parameters for the onset of atrial fibrillation in patients 
with essential hypertension. Am. Heart J. 2000; 139: 814–819.
12. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, inci-
dence, prognosis, and predisposing conditions for atrial fibrillation: 
population-based estimates. Am. J. Cardiol. 1998; 82 (suppl.): 
2N–9N.
13. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemi-
ologic features of chronic atrial fibrillation: the Framingham study. 
N. Engl. J. Med. 1982; 306: 1018–1022.
14. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. 
The natural history of atrial fibrillation: incidence, risk factors, and 
prognosis in the Manitoba Follow-Up Study. Am. J. Med. 1995; 
98: 476–484.
15. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a caus-
ative agent, risk factor for complications, and potential therapeutic 
target. Am. J. Cardiol. 2003; 91(10A): 9G–14G.
16. Andrade J., Khairy P., Dobrev D., Nattel S. The clinical profile and 
pathophysiology of atrial fibrillation: relationships among clinical 
features, epidemiology, and mechanisms. Circ. Res. 2014; 114: 
1453–1468.
17. Chodór P., Białkowska B., Hapeta B. et al. Evaluation of factors 
affecting persistence of atrial fibrillation in patients with concomi-
tant atrial flutter treated with percutaneous radiofrequency current 
ablation of the right atrial cavotricuspid isthmus. Kardiol. Pol. 2013; 
71: 247–252.
18. Heist E.K., Chalhoub F., Barrett C., Danik S., Ruskin J.N., Mansour 
M. Predictors of atrial fibrillation termination and clinical success 
of catheter ablation of persistent atrial fibrillation. Am. J. Cardiol. 
2012; 110: 545–551.
19. Mohanty S., Mohanty P., Trivedi C. et al. Association of pretreatment 
with angiotensin-converting enzyme inhibitors with improvement in ab-
lation outcome in atrial fibrillation patients with low left ventricular ejec-
tion fraction. Heart Rhythm 2015 Jun 5. pii: S1547-5271(15)00697-9. 
doi: 10.1016/j.hrthm.2015.06.007. [Epub ahead of print].
20. Pokushalov E., Romanov A., Katritsis D.G. et al. Renal denervation 
for improving outcomes of catheter ablation in patients with atrial 
fibrillation and hypertension: early experience. Heart Rhythm 2014; 
11: 1131–1138.
